May 8, 2008

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

 

Kim Angelastro
Publicis Consultants / PR
+1 (212) 527-8866
kimangelastro@publicis-pr.com

 

LifeVest Fully Automatic Wearable Defibrillator and AutoPulse Non-Invasive Cardiac Support Pump Showcased at Heart Rhythm Exposition 

Distinguished Panel Discusses Out of Hospital Protection for SCA Patients at HRS Symposium

May 1, 2008CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it will display its range of resuscitation products—including the LifeVest® wearable defibrillator and the AutoPulse®  Non-invasive Cardiac Support Pump—in Booth #529 at the Heart Rhythm 2008 Exposition in San Francisco May 15-17th.

ZOLL LifeVest: First and Only Wearable Defibrillator

The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing constant monitoring, immediate protection, and peace of mind. The LifeVest monitors the heart constantly and records patient data to help diagnose and treat life-threatening arrhythmias. If a patient is unconscious, the device continues to give alarms and spoken warnings to bystanders that a treatment shock is about to be delivered. The entire event, from arrhythmia detection to the automatic delivery of a defibrillation shock, can take less than a minute. This unique, non-invasive technology has been worn by nearly 9,000 patients, and has a 99% first shock success rate for treating patients in SCA without requiring bystander intervention.

AutoPulse Non-invasive Cardiac Support Pump

The AutoPulse Non-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse has been shown to improve survival to discharge in a major study published in the Journal of the American Medical Association (JAMA)*.

The AutoPulse offers a significant advantage over manual CPR because it moves more blood, more consistently, than is possible with human hands. AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion, while freeing clinicians in the catheterization lab to perform procedures with optimal vascular access and minimal visual compromises.

“In the cath lab, the use of AutoPulse means no compromises between PCI and other actions,” said Richard A. Packer, President and Chief Executive Officer of ZOLL.  “This exclusive technology offers the additional benefit of safeguarding staff from X-ray exposure as well as maintaining the integrity of a sterile working environment.”

In addition the LifeVest and AutoPulse, ZOLL will also display:

R Series, a Code-Ready defibrillator that is simple, smart, and ready to use. It offers a OneStep™ system to simplify and speed up deployment of pacing and defibrillation therapy. It also offers smart tools to help clinicians improve CPR performance, which is important since more than half of in-hospital codes involve non-shockable rhythms and, in such cases, the only treatment is high-quality CPR with minimal interruptions.

 

The R Series features both ZOLL’s Real CPR Help® and new patented See-Thru CPR™ technology. See-Thru CPR helps minimize interruptions in CPR—one of the key recommendations of the American Heart Association’s (AHA) Guidelines for Advanced Cardiac Life Support—by extracting CPR artifact and showing a “filtered” ECG on the defibrillator screen. It allows rescuers to see organized cardiac rhythm without stopping compressions.

 

  • CodeNet®, which is the first software system that allows hospital teams to better document, manage, and review cardiac arrest event and resuscitation information. CodeNet brings new improvements and efficiencies in data capture, event time synchronization, and case and aggregate reporting. It is the only system that time stamps logged events and synchronizes these times with defibrillator data, providing clinicians with a complete and accurate timeline of an entire cardiac arrest event.
  • M Series® CCT, which offers ZOLL’s superior biphasic defibrillation, external pacing, complete monitoring, and a large full-color display in a single portable unit. The M Series CCT features a three-channel display for ECG and two invasive pressures with ranges covering arterial, pulmonary arterial, central venous, or intracranial, as well as two temperature channels. It also provides all the non-invasive parameter options including SpO2, EtCO2, NIBP, and fully interpretive 12-lead ECG.

 

Breakfast Symposium: "Saving Lives with the Wearable Defibrillator"

ZOLL will host a breakfast symposium from 6:00 a.m. to 7:45 a.m. Friday, May 16th at the San Francisco Marriott, featuring a distinguished panel who will discuss sudden death risk and innovative methods of protection.  Topics that will be covered include identifying patients who are at high risk for sudden death, alternative prevention methods, and the limits and benefits of wearable defibrillators.

CME credits for physicians and CEU credits for nurses attending the event is available. Pre-registration can be completed online at www.zoll.lifecor.com/hrssymposium.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See Thru CPR™, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. 2008 marks the 25th anniversary of ZOLL’s resuscitation product development. For more information, visit www.zoll.com.

 

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 5, 2008. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

 

Copyright © 2008 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, CodeNet, LifeBand, LifeVest, M Series and Real CPR Help are registered trademarks of ZOLL Medical Corporation. Code-Ready, One-Step, See-Thru CPR and R Series are trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.

 

*Ong ME, Ornato JP et al. JAMA. 2006;295(22).